FY2026 EPS Estimates for Danaher Co. Decreased by Analyst (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Investment analysts at Zacks Research decreased their FY2026 earnings per share (EPS) estimates for Danaher in a research note issued to investors on Tuesday, October 1st. Zacks Research analyst R. Department now forecasts that the conglomerate will post earnings of $9.56 per share for the year, down from their previous forecast of $9.57. The consensus estimate for Danaher’s current full-year earnings is $7.59 per share.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. During the same quarter in the previous year, the business earned $2.05 earnings per share. The company’s revenue for the quarter was down 2.9% compared to the same quarter last year.

DHR has been the subject of a number of other research reports. Bank of America boosted their price target on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Stifel Nicolaus boosted their price target on Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. The Goldman Sachs Group boosted their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a report on Wednesday, July 24th. Royal Bank of Canada restated an “outperform” rating and set a $300.00 target price on shares of Danaher in a report on Friday, September 6th. Finally, Leerink Partners upped their target price on Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and an average target price of $282.12.

Danaher Stock Down 0.2 %

Shares of NYSE DHR opened at $270.03 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. The firm has a market capitalization of $200.01 billion, a price-to-earnings ratio of 45.77, a PEG ratio of 4.55 and a beta of 0.83. The stock has a 50 day moving average price of $271.07 and a 200 day moving average price of $258.56. Danaher has a 52-week low of $182.09 and a 52-week high of $281.70.

Danaher Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.40%. The ex-dividend date of this dividend is Friday, September 27th. Danaher’s payout ratio is 18.31%.

Insider Activity at Danaher

In related news, CEO Rainer Blair sold 9,007 shares of the company’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares of the company’s stock, valued at $27,435,240. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $280.00, for a total value of $2,521,960.00. Following the sale, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 39,659 shares of company stock valued at $11,042,433 in the last ninety days. Company insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Oak Thistle LLC acquired a new stake in Danaher during the 2nd quarter worth about $363,000. Caden Capital Partners LP grew its position in Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares during the period. HighPoint Advisor Group LLC purchased a new stake in shares of Danaher during the 4th quarter worth about $2,614,000. Norden Group LLC purchased a new stake in shares of Danaher during the 1st quarter worth about $4,151,000. Finally, Duality Advisers LP purchased a new stake in shares of Danaher during the 1st quarter worth about $5,573,000. 79.05% of the stock is owned by institutional investors and hedge funds.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.